•	PA Request Crite

## CAREFIRST - CF FACETS FEP RSK VF Clindamycin, Erythromycin Topical Limit-Post Limit (VF Standard)

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 888-836-0730. Please contact CVS/Caremark at 877-203-1681 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Clindamycin, Erythromycin Topical Limit-Post Limit (VF Standard).

Patient Informat	ion						
Patient Name:							
Patient Phone:							
Patient ID:							
Patient Group No:							
Patient DOB:							
Prescribing Physician							
Physician Name:							
Physician Phone:							
Physician Fax:	n Fax:						
Physician Address:	hysician ddress:						
City, State, Zip:							
Drug Name (spe	cify drug)						
Quantity: Frequency: Strength:							
Route of Administration: Expected Length of Therapy:							
Diagnosis:	ICD Code:						
Comments:							
Please check th	e appropriate answer for each applicable question.						
Is this requested drug being prescribed for the treatment of acne vulgaris?		Y		N			
2. Is the reque	ested drug being used in a footbath?	Y		N			
<ol> <li>Does the patient require MORE than the plan allowance PER MONTH of any of the following: A) 120gm or mL of Erythromycin gel or solution (Erygel), B) 120mL of Clindamycin lotion or solution (Cleocin-T lotion, Cleocin-T solution), C) 150gm or mL of Clindamycin gel (Clindagel, Cleocin-T gel)?</li> </ol>		Y		N			
	dication requested is medically necessary for this patient. I further attest that the information be documentation supporting this information is available for review if requested by the cla						

plan sponsor, or, if applicable a state or federal regulatory agency.

## Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.